Dermata Therapeutics, Inc. (DRMA) stock forecast & analysis
0.9100
NasdaqCM · USDDelayed by 15 minutes
Up: +0.2467, +37.2%
1 analysis
Latest analysis: · verdict locked
- Open
- 0.7678
- Previous close
- 0.6633
- Day range
- 0.7678 – 1.18
- 52-week range
- 0.6030 – 4.66
- Volume (shares)
- 169.48M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 4.96M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 0.66
- Market cap
- 4.51M
Market Scanner’s AI analysis of Dermata Therapeutics, Inc. (DRMA), updated October 2026: Dermata Therapeutics' cosmetic study results and product launch contrasted with sustained stock price declines and consistent net losses.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Dermata Therapeutics, Inc. (DRMA) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Dermata Therapeutics' cosmetic study results and product launch contrasted with sustained stock price declines and consistent net losses.
Recent analyses for Dermata Therapeutics (DRMA) covered the announcement of positive topline results from a cosmetic study for its Tome Foundational Treatment, followed by its commercial launch and the opening of preorders. Market data indicated a bearish trend with the stock trading below its 50-day and 200-day SMAs, despite an unusually high Money Flow Index. The company's financial performance showed consistent net losses and negative operating income, though its balance sheet indicated a healthy ability to meet short-term obligations with no reported debt.
DRMA news & sentiment
News headlines highlighted positive developments including study results and a product launch. Social media discussion was not covered in the provided notes.
DRMA technical picture
The stock traded below its 50-day and 200-day SMAs, indicating a sustained downward trend. Momentum readings showed consistent negative price changes across multiple timeframes, while the RSI sat below the neutral mark. The MFI registered unusually high, suggesting strong buying pressure despite the price action.
Fundamentals
The company has consistently reported net losses and negative operating income. However, its balance sheet indicates a healthy ability to meet short-term obligations, with a strong current ratio and no reported total debt.
Factors discussed — upside
- Positive topline results from cosmetic study for Tome Foundational Treatment
- Commercial launch of Tome Foundational Treatment and opening of preorders
- Healthy current and quick ratios indicating ability to meet short-term obligations
- No reported total debt as of the latest quarter
- Unusually high Money Flow Index suggesting strong buying pressure
Factors discussed — risks
- Stock trading significantly below 50-day and 200-day simple moving averages
- Consistent negative 7-day, 30-day, and 91-day price changes
- Consistently reported net losses and negative operating income
- Market report profiling DRMA alongside other companies in the papulopustular rosacea market
- Product launch and study results
- Technical price trends
- Financial performance and balance sheet
- Market positioning
Summary updated .
DRMA technical indicators
Common technical indicators for DRMA, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 1.21 | Price below |
| 10-day exponential moving average | 0.95 | Price below |
| Relative strength index (14-day) | 39.91 | Neutral |
| MACD line (12/26/9) | -0.0979 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 0.81 – 1.32 | Price inside the bands |
Analyses
Recent DRMA.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-16 DRMA.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Dermata Therapeutics, Inc.?
- The bull case for Dermata Therapeutics centers on the successful announcement of positive topline results for its Tome Foundational Treatment, followed by its commercial launch and the opening of preorders. The company's financial health is supported by healthy current and quick ratios, no reported debt, and an unusually high Money Flow Index suggesting strong buying pressure.
- What are the risks for Dermata Therapeutics, Inc.?
- Risks for Dermata Therapeutics include the stock trading significantly below its key moving averages, with consistent negative price changes observed over multiple short-term periods. The company has also consistently reported net losses and negative operating income, alongside market reports profiling it within a competitive landscape.
- Is Dermata Therapeutics, Inc. bullish or bearish?
- Recent AI analyses of Dermata Therapeutics, Inc. examined factors on both sides. Discussed upside: The bull case for Dermata Therapeutics centers on the successful announcement of positive topline results for its Tome Foundational Treatment, followed by its commercial launch and the opening of preorders. The company's financial health is supported by healthy current and quick ratios, no reported debt, and an unusually high Money Flow Index suggesting strong buying pressure. Discussed risks: Risks for Dermata Therapeutics include the stock trading significantly below its key moving averages, with consistent negative price changes observed over multiple short-term periods. The company has also consistently reported net losses and negative operating income, alongside market reports profiling it within a competitive landscape. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Dermata Therapeutics, Inc.?
- News headlines highlighted positive developments including study results and a product launch. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Dermata Therapeutics, Inc.?
- Every analysis of Dermata Therapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Dermata Therapeutics, Inc.?
The bull case for Dermata Therapeutics centers on the successful announcement of positive topline results for its Tome Foundational Treatment, followed by its commercial launch and the opening of preorders. The company's financial health is supported by healthy current and quick ratios, no reported debt, and an unusually high Money Flow Index suggesting strong buying pressure.
What are the risks for Dermata Therapeutics, Inc.?
Risks for Dermata Therapeutics include the stock trading significantly below its key moving averages, with consistent negative price changes observed over multiple short-term periods. The company has also consistently reported net losses and negative operating income, alongside market reports profiling it within a competitive landscape.
Is Dermata Therapeutics, Inc. bullish or bearish?
Recent AI analyses of Dermata Therapeutics, Inc. examined factors on both sides. Discussed upside: The bull case for Dermata Therapeutics centers on the successful announcement of positive topline results for its Tome Foundational Treatment, followed by its commercial launch and the opening of preorders. The company's financial health is supported by healthy current and quick ratios, no reported debt, and an unusually high Money Flow Index suggesting strong buying pressure. Discussed risks: Risks for Dermata Therapeutics include the stock trading significantly below its key moving averages, with consistent negative price changes observed over multiple short-term periods. The company has also consistently reported net losses and negative operating income, alongside market reports profiling it within a competitive landscape. These are descriptive observations, not a recommendation.
What is the latest sentiment on Dermata Therapeutics, Inc.?
News headlines highlighted positive developments including study results and a product launch. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse Dermata Therapeutics, Inc.?
Every analysis of Dermata Therapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh DRMA.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.